Prevention of viral myocarditis with recombinant human leukocyte interferon alpha A/D in a murine model
A Matsumori,
CS Crumpacker,
and
WH Abelmann
Effects of recombinant human leukocyte interferon alpha A/D on experimental myocarditis due to encephalomyocarditis virus were investigated. Plaque reduction assays revealed that 50% of plaque formation in vitro in human amnion (FL) cells was inhibited by interferon alpha A/D (9.7 U/ml) when it was administered 24 hours before infection with the encephalomyocarditis virus. Four week old male DBA/2 mice were inoculated intraperitoneally with 10 plaque-forming units (pfu) of encephalomyocarditis virus. Interferon alpha A/D was administered subcutaneously (10(2) U/g body weight per day in Group 1, 10(3) U/g per day in Group 2 and 10(4) U/g per day in Group 3) starting 1 day before infection. It was also administered starting the same day in Group 4 and 1 day after virus inoculation in Group 5 (10(4) U/g per day in both groups). Control mice were injected with saline solution. Each group consisted of 10 mice; they were killed on day 4 for evaluation. Myocardial virus titers were significantly lower in Group 3 (8.2 +/- 25.2 X 10(2) pfu/mg, p less than 0.05) and Group 4 (3.0 +/- 5.5 X 10(3) pfu/mg, p less than 0.05) than in control mice (5.6 +/- 4.1 X 10(4) pfu/mg). Histologic examination showed extensive myocardial necrosis and cellular infiltration in all control mice, but no myocardial necrosis or cellular infiltration in Group 3 and less severe necrosis and infiltration in Group 4. There were no significant differences in myocardial virus titers or histologic changes between control mice and Group 1, 2 or 5.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
|
|
 
E. Padalko, D. Nuyens, A. De Palma, E. Verbeken, J. L. Aerts, E. De Clercq, P. Carmeliet, and J. Neyts
The Interferon Inducer Ampligen [Poly(I)-Poly(C12U)] Markedly Protects Mice against Coxsackie B3 Virus-Induced Myocarditis
Antimicrob. Agents Chemother.,
January 1, 2004;
48(1):
267 - 274.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W Mason
Myocarditis and dilated cardiomyopathy: An inflammatory link
Cardiovasc Res,
October 15, 2003;
60(1):
5 - 10.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. P. Liu and J. W. Mason
Advances in the Understanding of Myocarditis
Circulation,
August 28, 2001;
104(9):
1076 - 1082.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Kawai
From Myocarditis to Cardiomyopathy: Mechanisms of Inflammation and Cell Death : Learning From the Past for the Future
Circulation,
March 2, 1999;
99(8):
1091 - 1100.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Yamamoto, M. Shibamori, M. Ogura, Y. Seko, and M. Kikuchi
Effects of Intranasal Administration of Recombinant Murine Interferon-{gamma} on Murine Acute Myocarditis Caused by Encephalomyocarditis Virus
Circulation,
March 17, 1998;
97(10):
1017 - 1023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kodama, S. Zhang, H. Hanawa, M. Saeki, T. Inomata, K. Suzuki, S. Koyama, and A. Shibata
Effects of 15-Deoxyspergualin on Experimental Autoimmune Giant Cell Myocarditis of the Rat
Circulation,
February 15, 1995;
91(4):
1116 - 1122.
[Abstract]
[Full Text]
|
|
|
|
